after partnering to fund 18 high impact research internships across canada in 2021 and 2022 mitacs and  scotiabank are launching a third round of the scotiabank economic resilience research fund (serrf).

serrf is designed to help reduce the financial barriers for charities and not for profit organizations to access expertise from canadian academic institutions through the mitacs accelerate program.

through this third round of the program serrf funding will be awarded to up to 50 research internship projects to occur in the fall 2023.

the serrf has been launched to support research projects in three key focus areas that are central to scotiabank’s scotiarise initiative:

1. accelerate newcomer integration
   proposed research projects will explore the experiences of newcomers to canada (in the past three years) including immigrants, refugees, and temporary foreign workers to help fast track meaningful employment for newcomers to the country. integration essentials might include language, culture and life skills, training and help qualifying for and finding employment, and support networks.

2. increase high school graduation and post-secondary participation

proposed research projects will target disadvantaged populations, including canadian indigenous communities and at-risk youth to ultimately facilitate a higher rate of high school graduation and post-secondary participation. post-secondary education is defined broadly, to include university, college, and trades programs.

3. remove barriers to career advancement for disadvantaged groups

proposed research projects should be focused on one or more equity seeking groups that face obstacles of sexism, racism, or homophobia (e.g., people with disability, indigenous, veterans, lgbtq, women, and bipoc). the project should determine how to remove barriers to meaningful employment and find solutions to career entry and advancement.

successful projects will receive up to $12,750 in funding from scotiabank and mitacs to support a four to six month mitacs accelerate internship. the funding contribution from the serrf program reduces the required contribution from the not for profit or charity partner organization from $7,500 to $3,750.

this opportunity is time limited and interested projects must submit an expression of interest by april 5, 2023

more detail about the scotiabank economic resilience research fund and application process can be found in the program guide

for further information or to start the eoi development process please contact ncummings@mitacs.ca or reach out directly to serrf@mitacs.ca

since 1993, the canadian cancer society has recognized individuals who have made, and are making, valuable contributions to the cancer research ecosystem in canada through our awards for excellence in cancer research.

the ccs is pleased to launch the 2022 awards for excellence in cancer research nomination process. to see the 2021 winners of these awards, please visit their webpage.

the nomination deadline is monday, may 1, 2023 at 5pm et.

the canadian cancer society inclusive excellence prize

this award recognizes an individual who has demonstrated leadership and impact in the advancement of equity, diversity, inclusion and accessibility as it relates to the cancer research ecosystem in canada.

the canadian cancer society lifetime contribution prize

this award recognizes an investigator whose contributions to cancer research in canada extend beyond traditional research accomplishments and outputs.

the canadian cancer society robert l. noble prize

this award recognizes an outstanding investigator permanently residing in canada whose contributions have led to significant achievements in basic biomedical cancer research.

the canadian cancer society o. harold warwick prize

this award recognizes an outstanding investigator permanently residing in canada whose contributions have led to significant advances in cancer control in canada.

the canadian cancer society bernard and francine dorval prize

this award is given to an outstanding early career investigator* in canada whose basic biomedical cancer research contributions have the potential to lead to, or have already led to, improved understanding of cancer treatments and/or cures.

the canadian cancer society william e. rawls prize 

this award is given to an outstanding early career investigator* in canada whose research in cancer control research has the potential to lead to, or has already led to, important advances in cancer control.

*those who began their independent research career after december 31, 2009 are eligible for nomination.

for more information, click here. please read the guidelines carefully to ensure that nominations are submitted correctly by the deadline.

if any of these prizes are of interest, please contact please contact dr. batia stolar, associate vice-president, research & graduate studies, at avp.research@lakeheadu.ca

the research training awards objective is to support growth and foster innovation for the next generation of cancer researchers across canada at the master’s, doctoral and postdoctoral levels through a comprehensive approach including mentorship, training, and knowledge-sharing. these awards also aim to build inclusive capacity in cancer research and recognizing this ccs encourages and supports applicants from black and indigenous communities to apply for this opportunity.

with their funding partners, ccs anticipates that at least $5m may be awarded in this competition. the amounts per year, training budget and duration for the 3 different training levels are specified on their website.

abstract due: april 6, 2023 for master’s and phd 世界杯2022赛程表淘汰赛 , and may 1, 2023 for postdoctoral fellows

to view more important dates and the full funding opportunity details, please click here. 

the fy23 defense appropriations act provides funding for the ovarian cancer research program (ocrp) to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of service members, veterans, their family members, and all women impacted by this disease.  the managing agent for the anticipated funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy23 ocrp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

applications submitted to the fy23 ocrp must address one or more of the following areas of emphasis:

• understand the basic biology and etiology of ovarian cancer initiation, progression, metastasis, recurrence, genetics, proteogenomics and other critical events

• develop novel therapeutic strategies for treatment and prevention
• identify and develop new strategies for screening, early-stage detection, prevention, accurate diagnosis, and prognosis
• identify and implement strategies to improve the survivorship and quality of life
• address health disparities
• improve precision medicine

alternatively, with adequate justification, applications may identify and address another area of importance related to the ovarian cancer. justification must be provided in the application.

https://cdmrp.health.mil/funding/ocrp

clinical trial award – letter of intent due may 26, 2023

independent investigators at all academic levels.

supports rapid implementation of clinical trials with the potential to have a significant impact on ovarian cancer.

proposed projects may range from small, proof-of-concept trials through large-scale, definitive trials, including early-phase or pilot clinical trials (phase 0, 1, or 1/2).

preliminary data are required. larger, more-definitive clinical trials, including expansion of previous promising pilot trials, must include preliminary data with respect to safety in an ovarian cancer population.

•the maximum allowable funding for the entire period of performance is $2,000,000 for direct costs.

•indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

•the maximum period of performance is 4 years.

new! clinical translational research award – letter of intent due may 26, 2023

the principal investigator (pi) must be at or above the level of assistant professor (or equivalent).

supports correlative studies that address translational research in high-impact or unmet needs in ovarian cancer and have a clinical emphasis. 

•applications focused on the following ocrp priority are encouraged:

‒utilize precision medicine and computational approaches that identify individual tumor characteristics and predictive biomarkers across diverse groups to optimize patient care and outcomes.

•clinical trials are not allowed.

•the maximum allowable funding for the entire period of performance is $2,000,000 for direct costs.

•indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

•the maximum period of performance is 4 years.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420.

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the ocrp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.health.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

for more information, please contact jill sherman at intl.research@lakeheadu.ca.

the fy23 defense appropriations act provides funding for the arp to support research of exceptional scientific merit and innovation with high impact that focuses on autism spectrum disorders (asd).  the managing agent for the anticipated funding opportunities is the cdmrp at the u.s. army medical research and development command (usamrdc).

the fy23 arp funding opportunity announcements for the following award mechanisms are posted on the grants.gov website. 

https://cdmrp.health.mil/funding/arp

clinical trial award – preproposal due april 19, 2023

investigators at or above the level of assistant professor (or equivalent)

or

early-career investigator partnering pi option:  investigators at or above the level of assistant professor (or equivalent) may collaborate on a single application with a young investigator (at the level of postdoctoral fellow up to early-career independent faculty) who meets the following criteria as of the application submission deadline date:

must be in a current postdoctoral training position or have completed postdoctoral training by the application deadline.

is no more than 7 years from the receipt of a terminal degree.

has the freedom to commit at least 50% time to the project.

•   supports research with the potential to have a major impact on the treatment and/or management of asd.

•   preliminary data relevant to the proposed project are required.

•   early-career investigator partnering pi option supports the development of young investigators pursuing or wishing to pursue a career in asd clinical trial research.

•   pre-application submission is required; application submission is by invitation only.

• ·    the maximum period of performance is 4 years.
• ·    single pi:  the maximum allowable funding for the entire period of performance is $1,900,000 in direct costs (plus indirect costs).
• ·    early-career investigator partnering pi option:  the maximum allowable funding for the entire period of performance is $2,200,000 for direct costs (plus indirect costs).
• ·    indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

idea development award – preproposal due april 19, 2023

investigators at or above the level of assistant professor (or equivalent)

• ·    supports the development of innovative, high-impact ideas that advance the understanding of asd and   ultimately lead to improved outcomes.
• ·    preliminary data are required.
• ·    partnering pi option:  up to two investigators may collaborate on a single application, each of whom will be recognized as a pi and receive a separate award.

pre-application is required; application submission is by invitation only.

• ·    the maximum period of performance is 3 years.
• ·    single pi or partnering pi option:  the maximum allowable funding for the entire period of performance is $550,000 in direct costs (plus indirect costs).
• ·    indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

career development award – preproposal due april 19, 2023

independent investigators at or below the level of assistant professor (or equivalent)

or

established independent investigators in an area other than autism spectrum disorder (asd) at or above the level of assistant professor (or equivalent) and seeking to transition to a career in asd, thereby bringing their expertise to the field

• ·    investigators must not have received a career development award (or equivalent) previously from any program within the congressionally directed medical research programs.
• ·    investigators must not have received more than $300,000 in total direct costs for previous or concurrent asd research as a principal investigator (pi) of one or more federally or privately funded non-mentored, peer-reviewed grants.
• ·    investigators must hold a ph.d., m.d., m.d./ph.d., or equivalent at time of pre-application submission.
• ·    supports early-career, independent investigators and/or the transition of established investigators from other research fields to conduct:

○    innovative, high-impact ideas or

○    early-phase, proof-of-principle clinical trials with the potential to have a major impact on asd

• ·    preliminary data relevant to the proposed project are required.

pre-application is required; application submission is by invitation only.

• ·    the maximum period of performance is 3 years.
• ·    the maximum allowable funding for the entire period of performance is $550,000 for direct costs.
• ·    indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

a pre-application is required and must be submitted through the electronic biomedical research application portal (ebrap) at https://ebrap.org prior to the pre-application deadline.  all applications must conform to the final funding opportunity announcements available for downloading from the grants.gov website.  the application package containing the required forms for each award mechanism will also be found on grants.gov.  a listing of all cdmrp and other usamrdc extramural funding opportunities can be obtained on the grants.gov website by performing a basic search using cfda number 12.420. 

for email notification when announcements are released, subscribe to program-specific news and updates under “email subscriptions” on the ebrap homepage at https://ebrap.org.  for more information about the arp or other cdmrp-administered programs, please visit the cdmrp website (https://cdmrp.health.mil).

point of contact:

cdmrp help desk
301-682-5507
help@ebrap.org

 for more information, please contact jill sherman at intl.research@lakeheadu.ca.

the goals of this funding opportunity are to summarize current evidence-based knowledge in canada, to identify areas of research strengths and gaps and to mobilize this knowledge for dissemination to relevant stakeholders.

the objectives of this funding opportunity are to:

• generate knowledge syntheses that will identify evidence-gaps and build evidence-based knowledge related to the promotion of brain health and reduction of risk for age-related cognitive impairment;
• mobilize knowledge on the current state of science that is relevant, equitable and accessible (i.e., that identifies the current state of knowledge and gaps and is communicated effectively); and,
• strengthen research excellence and ensure maximum research impact through consideration of diverse biological and/or socio-cultural identity factors in research design, including diverse, equitable and inclusive research methods, such as those based in indigenous ways of knowing.

the specific objectives of the knowledge mobilization component are to:

• enhance a common understanding between stakeholders on promotion of brain health and risk reduction for age-related cognitive impairment;
• generate accessible km products for dissemination that are tailored to relevant stakeholders based on the knowledge synthesis and includes equity, diversity and inclusion and indigenous rights considerations, as appropriate;
• foster collaboration and partnerships between stakeholders; and,
• increase usefulness and relevant uptake of evidence/knowledge by stakeholders, including partners and knowledge users.